問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Hualien Tzu Chi Hospital (在職)

Division of Urology

更新時間：2023-09-19

郭漢崇
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭漢崇

List

13Cases

2007-11-01 - 2009-03-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2007-08-01 - 2008-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2006-04-01 - 2007-03-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-07-01 - 2016-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2008-12-08 - 2009-12-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-07-31 - 2020-01-31

Phase III

A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Imidafenacin in Patients with Overactive Bladder

  • Condition/Disease

    Overactive Bladder

  • Test Drug

    Uritos

Participate Sites
12Sites

Terminated11Sites

2014-10-01 - 2024-12-30

Phase II

A PHASE II, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MCS® IN PROSTATE CANCER PREVENTION

  • Condition/Disease

    PROSTATE CANCER

  • Test Drug

    MCS®

Participate Sites
21Sites

Recruiting6Sites

Study ended15Sites

2009-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2014-06-17 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-09-01 - 2014-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB